SCHEMBL3011233

SCHEMBL3011233

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(C)cc4)CC3)n2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
STAT3 P40763 1/20 0.49
TSHR P16473 2/20 0.48
POLB P06746 1/20 0.48
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 3/20 0.46
USP2 O75604 2/20 0.46
MAPT P10636 1/20 0.46
RECQL P46063 1/20 0.46
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012247 0.94 LMNA (0.54) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL3013884 0.93 TSHR (0.53) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL3004835 0.92 HDAC3 (0.47) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL3007865 0.92 GAA (0.49) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL3007522 0.92 TSHR (0.45) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL3011204 0.92 MAPT (0.56) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL3008375 0.91 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL3015597 0.90 HSD11B1 (0.47) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL3011920 0.89 KMT2A (0.47) ALDH1A1KDM4ESMN1; SMN2LMNAHTT
SCHEMBL3017911 0.89 HTT (0.54) ALDH1A1KDM4ESMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885KDM4E 4398/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.